Evidence map›Paper›PMID 21521850›Full record

ArticleJAMA2011

Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.

Teppei Morikawa, Aya Kuchiba, Mai Yamauchi, Jeffrey A Meyerhardt, Kaori Shima, Katsuhiko Nosho, Andrew T Chan, Edward Giovannucci, Charles S Fuchs, Shuji Ogino

Registry-linked trialAbstract read
In one paragraph

Article in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01753245 (CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS VULGARIS, WITH OR WITHOUT ARTHRITIS, TREATED WITH ANTI-TNF IN REAL CLINICAL PRACTICE. ANALYSIS OF THE INFLUENCE OF METABOLIC SYNDROME ON TREATMENT EFFICACY.), which is not on this map. Cited by 126 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 8 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01753245 unknown statusnot on this mapstarted 2012, after this paper: background citation

Cardiovascular risk factors in a spanish population of patients with moderate-to-severe psoriasis vulgaris, with or without arthritis, treated with anti-tnf in real clinical practice. analysis of the influence of metabolic syndrome on treatment efficacy.

TypeobservationalSponsorJuan RuanoRan2012 to 2014Enrolled300ConditionsPsoriasis Vulgaris, Metabolic Syndrome
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 8 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Association ofGenetics research · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Expression profiling of archival tumors for long-term health studies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
    Pooled it
  8. Pooled it
  9. Trial
  10. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Trial
  11. Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Teppei MorikawaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA.
Aya Kuchiba
Mai Yamauchi
Jeffrey A Meyerhardt
Kaori Shima
Katsuhiko Nosho
Andrew T Chan
Edward Giovannucci
Charles S Fuchs
Shuji Ogino
Dana-Farber Cancer Institute · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SICINSKA, · 2007 to 2023
$33.2M
Risk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Epigenetic Events and Colorectal Cancer EpidemiologyR01CA151993 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2010 to 2014
$2.6M
Molecular Epidemiology of Colorectal CancerK07CA122826 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2007 to 2010
$634k
NCI NIH HHS K07 CA122826NCI NIH HHS K07CA122826NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P01CA55075NCI NIH HHS P01CA87969NCI NIH HHS P50 CA127003NCI NIH HHS P50CA127003NCI NIH HHS R01 CA050385NCI NIH HHS R01 CA137178NCI NIH HHS R01CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01CA151993
6 · The paper itself

Abstract

contextAlterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases.

objectiveTo test the hypothesis that CTNNB1 activation in colorectal cancer modifies prognostic associations of body mass index (BMI) and level of postdiagnosis physical activity. DESIGN, SETTING, AND PATIENTS: Two US prospective cohort studies (Nurses' Health Study and the Health Professionals Follow-up Study) were used to evaluate CTNNB1 localization by immunohistochemistry in 955 patients with stage I, II, III, or IV colon and rectal cancer from 1980 through 2004. A Cox proportional hazards model was used to compute the hazard ratio (HR) for mortality, adjusting for clinical and tumor features, including microsatellite instability, CpG island methylator phenotype, level of long interspersed nucleotide element 1 methylation, mutations in KRAS, BRAF, or PIK3CA, and tumor protein p53.

main outcome measuresColorectal cancer-specific mortality and overall mortality through June 30, 2009.

resultsIn obese patients (BMI ≥30), positive status for nuclear CTNNB1 was associated with significantly better colorectal cancer-specific survival (adjusted HR, 0.24 [95% confidence interval {CI}, 0.12-0.49], P <.001 for interaction; 5-year survival: 0.85 for patients with positive nuclear CTNNB1 status vs 0.78 for those with negative status) and overall survival (adjusted HR, 0.56 [95% CI, 0.35-0.90], P = .03 for interaction; 5-year survival: 0.77 for patients with positive nuclear CTNNB1 status vs 0.74 for those with negative status), while CTNNB1 status was not associated with prognosis among nonobese patients (BMI <30). Among patients with negative status for nuclear CTNNB1 and cancer in stages I, II, or III, postdiagnosis physical activity was associated with better colorectal cancer-specific survival (adjusted HR, 0.33 [95% CI, 0.13-0.81], P = .05 for interaction; 5-year survival: 0.97 for ≥18 vs 0.89 for <18 metabolic equivalent task hours/week), while postdiagnosis physical activity was not associated with colorectal cancer-specific survival among patients with positive status for nuclear CTNNB1 (adjusted HR, 1.07 [95% CI, 0.50-2.30]).

conclusionsAmong obese patients only, activation of CTNNB1 was associated with better colorectal cancer-specific survival and overall survival. Postdiagnosis physical activity was associated with better colorectal cancer-specific survival only among patients with negative status for nuclear CTNNB1. These molecular pathological epidemiology findings suggest that the effects of alterations in the WNT-CTNNB1 pathway on outcome are modified by BMI and physical activity.

Indexed as

Body Mass IndexExerciseAgedbeta CateninColorectal NeoplasmsCpG IslandsFemaleHumansImmunohistochemistryLife StyleMaleMicrosatellite InstabilityMiddle AgedObesityPrognosisProspective Studiesbeta CateninCTNNB1 protein, humanWnt Proteins

Identifiers

PMID21521850
PMCPMC3087286
OpenAlexW2023899769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.